TI
NKTR icon

Trexquant Investment’s Nektar Therapeutics NKTR Stock Holding History

Trexquant Investment’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.96M Buy
56,680
+1,204
+2% +$88.1K 0.02% 869
2026
Q1 		$3.99M Buy
55,476
+36,655
+195% +$2.09M 0.03% 747
2025
Q4 		$796K Sell
18,821
-72,659
-79% -$4.07M 0.01% 1250
2025
Q3 		$5.21M Buy
+91,480
New +$3.03M 0.05% 539
2020
Q4 		– Sell
-2,388
Closed -$594K – 1344
2020
Q3 		$594K Sell
2,388
-1,543
-39% -$485K 0.04% 614
2020
Q2 		$1.37M Sell
3,931
-646
-14% -$202K 0.09% 300
2020
Q1 		$1.23M Buy
4,577
+2,715
+146% +$840K 0.09% 346
2019
Q4 		$603K Buy
+1,862
New +$540K 0.04% 504
2018
Q4 		– Sell
-4,623
Closed -$4.23M – 1220
2018
Q3 		$4.23M Sell
4,623
-371
-7% -$317K 0.32% 87
2018
Q2 		$3.66M Buy
4,994
+4,759
+2,025% +$5.49M 0.25% 126
2018
Q1 		$374K Buy
+235
New +$303K 0.03% 728
2017
Q2 		– Sell
-3,806
Closed -$1.34M – 1054
2017
Q1 		$1.34M Buy
3,806
+170
+5% +$38.2K 0.17% 152
2016
Q4 		$669K Buy
3,636
+2,095
+136% +$426K 0.11% 322
2016
Q3 		$397K Sell
1,541
-110
-7% -$28.3K 0.09% 371
2016
Q2 		$352K Buy
+1,651
New +$369K 0.05% 605
2016
Q1 		– Sell
-1,160
Closed -$293K – 1087
2015
Q4 		$293K Sell
1,160
-215
-16% -$44.2K 0.03% 856
2015
Q3 		$226K Sell
1,375
-278
-17% -$49.2K 0.02% 941
2015
Q2 		$310K Sell
1,653
-4,107
-71% -$707K 0.03% 804
2015
Q1 		$950K Buy
5,760
+4,147
+257% +$852K 0.1% 392
2014
Q4 		$375K Buy
+1,613
New +$345K 0.07% 589

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Trexquant Investment's NKTR Position: Q2 2026 in Review

Trexquant Investment increased its Nektar Therapeutics (NKTR) stake by 2.2% in Q2 2026, buying an estimated $88.1K and bringing the position to 56,680 shares worth $3.96M. The position accounts for 0.02% of the portfolio, ranked #869.

Trexquant Investment first reported a position in NKTR in Q4 2014 and has held it in 20 quarters since. The position peaked at $5.21M in Q3 2025. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Trexquant Investment held 56,680 shares of Nektar Therapeutics worth $3.96M as of Q2 2026.
  • Trexquant Investment bought 1,204 Nektar Therapeutics shares in Q2 2026, an estimated $88.1K.
  • Nektar Therapeutics made up 0.02% of Trexquant Investment's portfolio in Q2 2026, its #869 holding.
  • Trexquant Investment first reported a position in Nektar Therapeutics in Q4 2014 and has held it in 20 quarters since.
  • Trexquant Investment's Nektar Therapeutics position peaked at $5.21M in Q3 2025.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.